Moreover, the most adequate timing for TLR-9 agonist administration is likely to be not yet determined, as an appropriate period between TLR-9 agonists and chemotherapy administration may be necessary to avoid the suppression of anti-cancer immune response by cytotoxic agents. This evidence concerns the gene TLR9 and cancer.